The global central lab market size was valued at USD 31.10 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.50% from 2023 to 2030. The growth can be attributed to the increasing investment in R&D and the increased focus of sponsors & investigators on reducing research costs. The outsourcing of central lab work is further driving the market growth. These laboratories faced difficulties in sample movement across borders during the SARS-CoV-2 pandemic, stringent regulations influenced the business adversely. Furthermore, pharmaceutical and biopharmaceutical companies are increasingly preferring services from the CROs that provide central lab services as a part of their integrated service models. Better integration of central lab and bioanalytical services aids in easier patient management.
Changes in the demand side significantly impacted the movement of business in central labs. Consumers are increasingly looking for a customized approach based on their specific needs. Logistics and sample management owing to increased monitoring on an individual basis of the candidates based on the diseases makes the personalized approach significantly advantageous for the customer.
The demand for innovative drugs for diseases is rising, which can be attributed to increasing awareness and personal approaches to treatment. Furthermore, the accelerating pace of innovation cycles is leading products to enter into preclinical stages. Thereby, creating a market opportunity for the central labs.
The high cost of treating the geriatric population with multiple diseases is further accelerating the demand for cost-effective products. Novel products also create revenue streams for companies, which increases the industry’s focus on R&D. This allows the companies to build robust product portfolios with strong Intellectual Property Rights (IPR). As a result, there will be more opportunities for clinical trials and a greater demand for central lab services.
The biomarker services segment held the highest market share of 38.30% in 2022 and is expected to witness the highest growth during the forecast period. The growth of the segment can be attributed to the co-development of diagnostics & drugs and the selection of appropriate assay development platforms that provide new opportunities for the integration of biomarkers in clinical processes. In the case of central labs, integration of biomarker services with other trial support offerings can strengthen the offerings by increasing the feasibility of the evaluation of biomarker assays.
Genetic services are gaining a foothold due to the increasing significance of genetic analysis in clinical studies and is expected to grow at a CAGR of 7.8% over the forecast period. Understanding the underlying genetic factors can aid in the development of targeted therapies for a variety of diseases, such as cancer and inheritable diseases. Furthermore, genetic differences in pathways for drug metabolism may alter a patient’s response to treatment. Hence, genetic services can add value to trial analysis and help guide treatment options.
The pharmaceutical companies end-use segment held the highest market share of 45.34% in 2022. Clinical trials for new pharmaceuticals are supported by central labs, as are genetic testing services for disorders such as Alzheimer's disease, sickle cell anemia, and Parkinson's disease. As a result, the increasing number of clinical studies and the rising prevalence of genetic illnesses are expected to fuel the expansion of the market during the forecast period. Furthermore, as pharmaceutical firms are continually looking for ways to save costs in drug development and manufacturing, the demand for central labs is expected to surge in the future.
The academic and research institutes segment held a significant market share in 2022, owing to the increasing trend among pharmaceutical companies to outsource non-core activities or development-related processes to off-shore sites to save money. Hence, by opting for the help of CROs, several operational benefits can be obtained. Moreover, factors driving the market include an increase in the number of diseases, the development of novel treatments & medications, and significant research funding, proposals, & financing from governments to build innovative testing processes.
North America dominated the market with a share of 41.55% in 2022. The market is collectively driven by a significant percentage of R&D in the region along with the presence of a supportive regulatory landscape. Moreover, the high prevalence of infections such as Sexually Transmitted Infections (STI) & tuberculosis in the region is also anticipated to propel the demand for clinical research pertaining to the development of diagnostics devices and therapeutics.
The Asia Pacific is expected to witness the fastest growth of 7.8% in the market due to the increasing adoption of central lab services in the region. This can be attributed to rapid economic growth and an increase in R&D investment by countries, such as China and Japan, which has led to a rise in the number of clinical trials conducted.
A market expansion plan is a method for organizations to grow after they have exhausted their existing channels. This is the most widely used method by companies to attract more customers. In September 2020, LabConnect has announced the addition of its Johnson City facilities to accommodate its massive development in cell and gene therapy, as well as immuno-oncology research. The company after relocating its headquarters to Tennessee is increasing the capacity of its biorepository for specimen storage as well as its clinical trial kit manufacturing capability. Some of the key players in the global central lab market include:
ACM Global Laboratories
Labconnect
Cerba Research
Eurofins Scientific
Medicover Integrated Clinical Services
Versiti
A.P. Møller Holding A/S
Ampersand Capital Partners
Lambda Therapeutics Research Ltd
Cirion Biopharma Research Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 3.34 billion |
Revenue forecast in 2030 |
USD 5.14 billion |
Growth rate |
CAGR of 6.50% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2019 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million, volume in thousands for instruments & million for reagents, and CAGR from 2023 to 2030 |
Report coverage |
Volume & Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Services, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
ACM Global Laboratories; Labconnect; Cerba Research; Eurofins Scientific; Medicover Integrated Clinical Services; Versiti; A.P. Møller Holding A/S; Ampersand Capital Partners; Lambda Therapeutic Research Ltd; Cirion Biopharma Research Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global central lab market report based on services, end use, and region:
Services Outlook (Revenue, USD Million, 2018 - 2030)
Genetic Services
Biomarker Services
Microbiology Services
Anatomic Pathology/Histology
Specimen Management & Storage
Special Chemistry Services
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Companies
Biotechnology Companies
Academic & Research Institutes
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global central lab market size was estimated at USD 3.10 billion in 2022 and is expected to reach USD 3.34 billion in 2023.
b. The global central lab market is expected to grow at a compound annual growth rate of 6.5% from 2023 to 2030 to reach USD 5.08 billion by 2030.
b. Biomarker services dominated the central lab market with a share of 38.30% in 2022. This is attributable to their use in discerning the disease mechanisms for the development of better therapeutics.
b. Key players operating in the central lab market are ACM Global Laboratories, LabConnect, Cerba Research, Eurofins Scientific, Medicover Integrated Clinical Services, Versiti, A.P. Møller Holding A/S, Ampersand Capital Partners, Lambda Therapeutics Research Ltd, and Cirion Biopharma Research Inc.
b. Key factors that are driving the central lab market growth include increasing investment in R&D and increased focus of sponsors & investigators on reducing research costs. The outsourcing of central lab work is further driving the market growth.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.